Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Genenta Science (GNTA)

Genenta Science SPA
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:GNTA
DateTimeSourceHeadlineSymbolCompany
06/05/202411:25GlobeNewswire Inc.Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd WiderNASDAQ:GNTAGenenta Science SPA
12/02/202421:05Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:GNTAGenenta Science SPA
08/02/202410:00GlobeNewswire Inc.Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid TumorsNASDAQ:GNTAGenenta Science SPA
20/10/202321:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GNTAGenenta Science SPA
06/09/202312:00GlobeNewswire Inc.Genenta to Present at Upcoming Scientific and Investor ConferencesNASDAQ:GNTAGenenta Science SPA
28/07/202308:00GlobeNewswire Inc.Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor TreatmentsNASDAQ:GNTAGenenta Science SPA
29/06/202312:00GlobeNewswire Inc.The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of GliomaNASDAQ:GNTAGenenta Science SPA
25/05/202311:04Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:GNTAGenenta Science SPA
16/05/202312:00GlobeNewswire Inc.Genenta to Provide Update on Lead Product Temferon™NASDAQ:GNTAGenenta Science SPA
12/05/202322:13Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-3)NASDAQ:GNTAGenenta Science SPA
01/05/202321:06Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:GNTAGenenta Science SPA
26/04/202312:00GlobeNewswire Inc.Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F FilingNASDAQ:GNTAGenenta Science SPA
21/04/202322:23Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:GNTAGenenta Science SPA
10/03/202321:49Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:GNTAGenenta Science SPA
10/02/202311:10Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:GNTAGenenta Science SPA
01/02/202322:29Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:GNTAGenenta Science SPA
22/12/202221:12Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:GNTAGenenta Science SPA
26/10/202223:45TipRanksMaxim Group Remains a Buy on Genenta Science SpA Sponsored ADR (GNTA)NASDAQ:GNTAGenenta Science SPA
25/10/202222:14Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:GNTAGenenta Science SPA
03/10/202212:17Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:GNTAGenenta Science SPA
25/07/202211:00GlobeNewswire Inc.AmCham Italy and Genenta Science Announce the Bowling Green Bull InitiativeNASDAQ:GNTAGenenta Science SPA
14/06/202222:12Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:GNTAGenenta Science SPA
15/06/200915:47PR Newswire (US)The following is an investment opinion release issued by EmergingStockReport.comNASDAQ:GNTA
15/05/200915:48PR Newswire (US)Stock Alerts on Market Movers: NGRN, RMBS, NVLS, LVS, GNTA, AN; Issued by Beacon EquityNASDAQ:GNTA
07/03/200900:36Dow Jones NewsGenta: FDA Favors Clinical Trial For Leukemia Drug GenasenseNASDAQ:GNTAGenta Inc.
06/03/200923:34Business WireFDA Appeal Decision Indicates that Genasense® Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory ...NASDAQ:GNTAGenenta Science SPA
13/02/200921:10Business WireGenta Incorporated Announces Fourth Quarter and Year End 2008 Financial Results and Corporate HighlightsNASDAQ:GNTAGenenta Science SPA
07/01/200918:02PR Newswire (US)Beacon Equity Issues Technical Trade Alerts on Newsworthy Market Movers: WLT, SSCC, FNSR, CHTR, STSI, GNTANASDAQ:GNTA
15/09/200813:05PR Newswire (US)Independent Monitoring Board Recommends Completion of Accrual to Genasense(R) Phase 3 AGENDA Trial in Advanced MelanomaNASDAQ:GNTA
07/08/200813:00PR Newswire (US)Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate HighlightsNASDAQ:GNTA
 Showing the most relevant articles for your search:NASDAQ:GNTA

Your Recent History

Delayed Upgrade Clock